Predictive values of procalcitonin for coinfections in patients with COVID-19: a systematic review and meta-analysis

ObjectivesTo assess the ability of procalcitonin (PCT)-a promising marker for coinfections-to predict coinfections in patients with COVID-19.MethodsIn this systematic review and meta-analysis, PubMed, Embase, Web of Science, Cochrane, the China National Knowledge Infrastructure (CNKI), and Wanfang were searched to identify eligible studies (up to August 30, 2021). Articles that reported the predictive value of PCT for coinfections in patients with COVID-19 were included. Individual and pooled sensitivities and specificities were reported, and I-2 was used to test heterogeneity. This study was prospectively registered on the International Prospective Register of Systematic Reviews (PROSPERO) database (registration number: CRD42021283344).ResultsFive studies involving a total of 2775 patients reported the predictive value of PCT for coinfections in patients with COVID-19. The sensitivity, specificity, and area under the curve of PCT in predicting coinfections in the pooled studies were 0.60 (95% CI 0.35-0.81, I-2 = 88.85), 0.71 (95% CI 0.58-0.81, I-2 = 87.82), and 0.72(95% CI 0.68-0.76) respectively.ConclusionsAlthough PCT has limited predictive value for coinfections in patients with COVID-19, lower PCT levels seem to indicate a decreased probability of having a coinfection.

Automated summary

This systematic review and meta-analysis assessed the ability of procalcitonin (PCT) as a potential marker for coinfections in patients with COVID-19. The results showed that PCT has limited sensitivity and specificity in predicting coinfections, but lower PCT levels seem to indicate a decreased probability of having a coinfection.